Stoke Therapeutics, Inc. $STOK Stock Position Cut by Skorpios Trust

Skorpios Trust cut its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 52.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,256,181 shares of the company’s stock after selling 3,650,000 shares during the quarter. Stoke Therapeutics makes up approximately 99.6% of Skorpios Trust’s holdings, making the stock its largest holding. Skorpios Trust owned about 5.96% of Stoke Therapeutics worth $36,958,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of STOK. GAMMA Investing LLC increased its holdings in Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after purchasing an additional 5,084 shares during the last quarter. AlphaQuest LLC acquired a new position in shares of Stoke Therapeutics in the 1st quarter worth approximately $72,000. US Bancorp DE grew its position in shares of Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after acquiring an additional 11,108 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Stoke Therapeutics in the 1st quarter worth approximately $92,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Stoke Therapeutics in the 1st quarter worth approximately $107,000.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 5,501 shares of Stoke Therapeutics stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the sale, the insider owned 18,469 shares of the company’s stock, valued at $366,979.03. The trade was a 22.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $25.07, for a total value of $250,700.00. Following the sale, the general counsel directly owned 11,831 shares in the company, valued at $296,603.17. The trade was a 45.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 185,180 shares of company stock valued at $4,129,406 in the last quarter. Corporate insiders own 9.50% of the company’s stock.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $32.52 on Thursday. The business’s fifty day moving average price is $24.20 and its two-hundred day moving average price is $15.32. The company has a market capitalization of $1.78 billion, a P/E ratio of 38.26 and a beta of 1.24. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17. The firm had revenue of $13.82 million for the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. On average, research analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on STOK shares. Chardan Capital reiterated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. BTIG Research lifted their target price on Stoke Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Weiss Ratings reissued a “sell (d+)” rating on shares of Stoke Therapeutics in a report on Wednesday, October 8th. Needham & Company LLC raised their price target on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Finally, Wedbush raised their price target on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $30.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.